Search

Emerging developments in dry eye

An estimated 344 million people worldwide suffer from dry eye [1]. This chronic syndrome is characterised by a vicious cycle of tear film hyperosmolarity, tear instability and corneal stress, leading to increased friction, inflammation, ocular surface damage and decreased visual...

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Capacity building for ophthalmic nursing in Ghana, Botswana and Tanzania

Ophthalmic nurses (ON) have been the backbone of eye health services in Africa since the mid-20th century and remain the largest single cadre of allied ophthalmic personnel in Commonwealth countries in Africa. Numbers are currently estimated at between 3500 and...

In conversation with Bernie Chang (RCOphth President)

We spoke to Professor Bernie Chang, President of the Royal College of Ophthalmologists, about his highlights so far, the curriculum update being delivered tomorrow, and the innovations required to run the Congress this year.

Retinal prosthetics: science fiction or a vision for the future?

“Is it a fact – or have I dreamt it – that, by means of electricity, the world of matter has become a great nerve, vibrating thousands of miles in a breathless point of time?” – Nathaniel Hawthorne, The House...

Mucormycosis: In conversation with Dr Deepak Haldipur and Dr Aditya Moorthy

COVID-19 has ravaged the world in the past 18 months. The second wave in many countries was deadlier than the first. Mucormycosis, infamously labelled ‘the black fungus’ has affected some countries, such as India, in epidemic proportions within this COVID...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...